BACKGROUND: Pertussis can cause significant morbidity in elderly patients, who can also
transmit this disease to infants and young children. There is little data available on the use of …

Background. In a previously reported double blind efficacy trial of a pertussis toxoid vaccine,
3450 infants were randomized to receive diphtheria-tetanus toxoids with or without pertussis …

Background Vaccination uptake at the individual level can be assessed in a variety of ways,
including traditional measures of being up-to-date (UTD), measures of UTD that consider …

Acellular pertussis vaccines provide protection against whooping cough with few adverse
effects. Their introduction to routine immunisation programmes would be facilitated by their …

Following concerns about the safety and reactogenicity profile of diphtheria, tetanus and
whole cell pertussis vaccines (DTwP), new and less reactogenic alternatives were …

Background In the United States, children receive five doses of diphtheria, tetanus, and
acellular pertussis (DTaP) vaccine before 7 years of age. The duration of protection after five …

We estimated the effectiveness of pertussis vaccination in reducing the clinical severity of
breakthrough disease among vaccinated individuals from a comprehensive follow-up study …

Vaccination against diphtheria, tetanus, and pertussis (DTP) has achieved great success in
infants and younger children in China. However, pertussis booster vaccination in older …

A second generation acellular pertussis vaccine (component pertussis vaccine) containing
purified pertussis toxin (PT) and filamentous hemagglutinin (FHA) was tested for its …

Background: Due to the resurgence of pertussis, many countries have revised the pertussis
immunization schedules and recommended booster doses of pertussis component vaccine …